This dataset contains summary data visualizations and clinical data from 67 samples from 67 patients as part an NCI-60 cell line project to compile NCI-60 cell line high-throughput and high-content data into CellMiner, a genomic and pharmacologic database created by the National Cancer Center Institute. The clinical data includes deidentified patient and sample IDs, mutation counts, detailed cancer...

This dataset contains summary data visualizations and clinical data from a sampling of 18 prostate tumor samples from 10 patients. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes deidentified patient and sample IDs, mutation count, and the fraction of genome that was altered. The data set also includes copy-number segment data downloadable as .seg...

TCGA Bladder Urothelial Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 413 carcinomas from 412 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

Author summary from Gene Expression Omnibus: "Transcriptome prolifing analysis was performed in 22Pc-EP cells to identify differentially regulated genes by enzalutamide and NRG1. 22Pc-EP cells were treated with androgen receptor inhibition (enzalutamide) or a HER3 ligand NRG1 for 48hrs." The data is from a study on tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer.

Summary from the GEO: "Patients with locally advanced prostate cancer after radical prostatectomy are candidates for secondary therapy. However, this higher risk population is heterogeneous. Many cases do not metastasize even when conservatively managed. Given the limited specificity of pathological features to predict metastasis, newer risk prediction models are needed. We report a validation study...

Summary from the GEO: "Clinicopathologic features and biochemical recurrence are sensitive, but not specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a genomic expression signature detected in the primary tumor represents true biological potential of aggressive disease and provides improved prediction of early prostate cancer metastasis. Methods: A nested...

Summary from the GEO: "Gene expression analysis of primary mouse prostate organoid culture with overexpression of FOXA1 Examination by genotypes and days elapsed prepared in 3 replicates." The study associated with the dataset further explains FOXA1 and how it connects to the dataset: "Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but the functional consequences...

Summary from the GEO: "To determine whether adding Decipher to standard risk stratification tools (CAPRA-S and Stephenson nomogram) improves accuracy in prediction of metastatic disease within 5 years after surgery in men with adverse pathologic features after RP. The study population consisted of 182 patients selected from 2,641 men who underwent RP at the Cleveland Clinic between 1987-2008 who...

Summary from the GEO: "Mutations in the FOXA1 transcription factor define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is unknown. By annotating the FOXA1 mutation landscape from 3086 human prostate cancers, we define two hotspots in the forkhead domain: Wing2 (~50% of all mutations) and R219 (~5%), a highly...

Summary from the GEO: "Radical prostatectomy (RP) is a primary treatment option for men with intermediate- and high-risk prostate cancer. Although many are effectively cured with local therapy alone, these men are by definition at higher risk of adverse pathologic features. It has been shown previously that genomic data can be used to predict tumor aggressiveness. Our objective was to evaluate genomic...